Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.
about
A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugsHIV, HCV, and Health-Related Harms Among Women Who Inject Drugs: Implications for Prevention and TreatmentOutlier populations: individual and social network correlates of solvent-using injection drug usersAssessing the feasibility of hepatitis C virus vaccine trials: results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study.Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012.Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunitiesRisk Factors Associated with Unsafe Injection Practices at the First Injection Episode among Intravenous Drug Users in France: Results from PrimInject, an Internet Survey.Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data.A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design.The Edinburgh Addiction Cohort: recruitment and follow-up of a primary care based sample of injection drug users and non drug-injecting controlsA trial to reduce hepatitis C seroincidence in drug users.Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort.Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012.Prevalence and incidence of HCV infection among Vietnam heroin users with recent onset of injection.Hepatitis C infection in non-treatment-seeking heroin users: the burden of cocaine injectionGender issues in the pharmacotherapy of opioid-addicted women: buprenorphine.Prisons as social determinants of hepatitis C virus and tuberculosis infections.Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review.Prescription opioid misuse and its relation to injection drug use and hepatitis C virus infection: protocol for a systematic review and meta-analysis.HCV seropositivity in inmates and in the general population: an averaging approach to establish priority prevention interventions.The Cedar Project: high incidence of HCV infections in a longitudinal study of young Aboriginal people who use drugs in two Canadian cities.The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug usersA multicentre sero-behavioural survey for hepatitis B and C, HIV and HTLV among people who inject drugs in Germany using respondent driven samplingControversies in and challenges to our understanding of hepatitis C.Injection risk behaviors among rural drug users: implications for HIV prevention.Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995-2004Drug use patterns in the presence of crack in downtown MontréalThe growing popularity of prescription opioid injection in downtown Montréal: new challenges for harm reduction.Hepatitis infection in the treatment of opioid dependence and abuse.Developing and validating a scoring tool for identifying people who inject drugs at increased risk of hepatitis C virus infection.A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugsMeta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment.Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).How can hepatitis C be prevented in the long term?Survival sex work involvement as a primary risk factor for hepatitis C virus acquisition in drug-using youths in a canadian setting.Quantifying hepatitis C transmission risk using a new weighted scoring system for the Blood-Borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ): applications for community-based HCV surveillance, education and prevention.Epidemiology of Injection Drug Use: New Trends and Prominent Issues.Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada.Establishing the Melbourne Injecting Drug User Cohort Study (MIX): rationale, methods, and baseline and twelve-month follow-up results
P2860
Q24629455-76615582-2B75-430A-B419-1BA7954BAFE4Q26991563-BFFCAF1E-7EA6-4D59-92C3-141F2CA6CC23Q28539716-DD2AEF81-9A07-4BC0-A32B-E2A031DFF7C7Q30208996-033AB19E-89BE-4461-93AA-78FBCB9FC09BQ30209037-60DC6292-0340-4102-927B-DA9DC74E516EQ30226978-6014CB76-66BC-4249-BA06-2721C8DBE11BQ30668946-6DEE58FE-FD40-462A-9846-6CD667675716Q30713067-32124282-2D30-4E6F-A91A-AA65E6CCC545Q33483115-ACDFF953-D2A2-4004-92CB-1B6BA210EDA9Q33534850-F6F3887B-4ADD-4D22-A90A-D608715EA46AQ33658861-FB97596E-AC26-4854-A683-C40FD712D1F7Q33691250-42E04D0A-DFA9-4677-9567-0D166402B81BQ33711886-3B7C853F-FE65-4EA0-8E53-751C39091897Q33754364-F4E4A663-FCDE-439E-805F-4FFDEE5E9346Q33760646-C5E5C67C-6373-44E0-83EA-CC84DC22CD9FQ33807411-81673AB8-9E14-4ABF-A07F-618EB04E856DQ33902953-12F9EA3A-0686-482D-9D61-3C215F12FD65Q34088235-C02C87F2-9F5E-478F-9C4C-4045801CCF6AQ34153684-66CE9187-A591-46B6-BE1A-3A7F196A190FQ34365104-F55C95B1-3895-4705-848D-968373C3333CQ34373050-887F6BB3-49F3-4327-8288-6FC9292D3B08Q34498633-DD24823B-29B0-408C-8B22-9A6075E9C2C3Q34584310-8CBCFF41-E43D-4BC1-BD62-40A5B15052E4Q34604806-1605E349-31CA-4202-A801-CD3FB985B82FQ34809845-F0AC5E27-4A5C-4C5E-B2EC-CFFFDEB3312EQ34870882-196832B8-C562-4A57-9F9B-8F6C56534EAAQ35106232-AC7A5760-5B41-42B0-9994-433C0E466907Q35179636-9D925E8B-4D4E-4422-A18D-C4D52A77C803Q35389163-B6BD41E2-BC63-4FBE-845B-10E5A6885656Q35659866-0D533344-DA71-4AB7-BC5C-BB398927FFADQ35889562-465B47F8-555B-4B17-9809-60E123403941Q35947066-542B5A02-B53F-4823-8C66-32E711439AD2Q36079786-F7C57DD2-0B18-4FD1-BF77-FD1617F7EE2FQ36123087-0EE2BDF3-3D73-4DF2-B079-01324DF8E1B2Q36226863-22AA203C-D30F-4457-BBDC-7126F6F5AA80Q36284570-B6EE2A61-73DC-4AF6-8759-D799FC0C9B7FQ36663249-8E2E4DB3-D392-4E9C-8918-B203F6BA78CEQ36744335-1437BAF1-6D77-4C6D-A186-D00D1873A9CFQ36922133-A99E15A3-0761-4FBB-8B8A-09C16D15B124Q36952990-F31D59BB-CFB7-46C3-9F6B-AB3C0656FE03
P2860
Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Incidence and risk factors for ...... cting drug users in Australia.
@en
Incidence and risk factors for ...... cting drug users in Australia.
@nl
type
label
Incidence and risk factors for ...... cting drug users in Australia.
@en
Incidence and risk factors for ...... cting drug users in Australia.
@nl
prefLabel
Incidence and risk factors for ...... cting drug users in Australia.
@en
Incidence and risk factors for ...... cting drug users in Australia.
@nl
P2093
P1433
P1476
Incidence and risk factors for ...... cting drug users in Australia.
@en
P2093
Bin Jalaludin
John M Kaldor
Kerry G Chant
Lisa Maher
Penny L Sargent
Rohan Jayasuriya
Tim Sladden
P2860
P304
P356
10.1111/J.1360-0443.2006.01543.X
P407
P577
2006-10-01T00:00:00Z